Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.9%

15 terminated/withdrawn out of 794 trials

Success Rate

90.6%

+4.1% vs industry average

Late-Stage Pipeline

11%

88 trials in Phase 3/4

Results Transparency

3%

5 of 145 completed trials have results

Key Signals

146 recruiting5 with results11 withdrawn

Enrollment Performance

Analytics

N/A
222(42.5%)
Phase 2
156(29.9%)
Phase 4
50(9.6%)
Phase 1
47(9.0%)
Phase 3
38(7.3%)
Early Phase 1
9(1.7%)
522Total
N/A(222)
Phase 2(156)
Phase 4(50)
Phase 1(47)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (794)

Showing 20 of 794 trials
NCT07737262Phase 3Not Yet Recruiting

Prophylactic NAC to Improve Platelet Engraftment After Haploidentical Transplantation in Severe Aplastic Anemia Patients

Role: lead

NCT07654036Not ApplicableCompleted

Preliminary Evaluation of a Large Language Model-Based Tool for Complex Surgical Decision Support in Lung Cancer

Role: lead

NCT07733037Phase 2Active Not Recruiting

Fecal Microbiota Transplantation for Steroid-resistant or Relapsed Immune Thrombocytopenia

Role: lead

NCT07335887Phase 2Recruiting

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

Role: lead

NCT07730593Not ApplicableCompleted

CBT-I for the Patients With Chronic Insomnia in China

Role: lead

NCT07725783Recruiting

Prospective Evaluation of Dynamic Serum ProGRP for Treatment Response Monitoring in Ewing Sarcoma

Role: lead

NCT07721558Not ApplicableNot Yet Recruiting

Effect of Inspired Oxygen Concentration on Postoperative Atelectasis After VATS Right Lobectomy

Role: lead

NCT07720011Phase 2Completed

Interim PET/CT-adapted Use of PD-1 Inhibitor Combined With De-escalated Chemotherapy-AVD in Classic Hodgkin Lymphoma

Role: lead

NCT05576389Phase 2Recruiting

Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study

Role: lead

NCT07717242Phase 2Recruiting

Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

Role: collaborator

NCT07714070Phase 2Not Yet Recruiting

Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia

Role: lead

NCT07711509Not ApplicableActive Not Recruiting

Autologous Fecal Microbiota Transplantation for Anal Function Recovery After Ileostomy Reversal in Rectal Cancer

Role: lead

NCT07672210Recruiting

PregnAncy-Related Aortic DISsEction in China

Role: collaborator

NCT07632664Not ApplicableRecruiting

Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients

Role: lead

NCT07238894Not ApplicableRecruiting

A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients

Role: lead

NCT07600164Phase 4Recruiting

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer

Role: lead

NCT07366112Phase 2Recruiting

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

Role: lead

NCT06970912Phase 2Recruiting

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Role: lead

NCT07564271Withdrawn

Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies

Role: lead

NCT07586735Recruiting

A Novel Conditioning Regimen for Haplo-HSCT in Older Patients With SAA

Role: lead